Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	8.48M
Revenue (ttm)	n/a
Net Income (ttm)	-11.62M
Shares Out	6.52M
EPS (ttm)	-2.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,885
Open	1.100
Previous Close	1.085
Day's Range	1.100 - 1.380
52-Week Range	0.720 - 10.050
Beta	0.59
Analysts	Strong Buy
Price Target	30.00 (+2,207.69%)
Earnings Date	May 13, 2025

About BCLI

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: BCLI
• Website: https://www.brainstorm-cell.com

Analyst Forecast

According to one analyst, the rating for BCLI stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target

$30.0

(2,207.69% upside)

Analyst Consensus: Strong Buy